A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers

An Exploratory Phase I Study in Healthy Volunteers of GI Transit Following Administration of the ß3-Adrenergic Receptor Agonist, Solabegron (Study B3I106248)

This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, retards the emptying of the colon and increases total colonic transit time.

Inclusion Criteria:

• Subjects with no evidence of current or past history suggestive of gastrointestinal disease or disorder or medical illness that could compromise interpretation of the study.
• no clinically significant laboratory results collected at the screening visit
• men: body weight greater than or equal to 50kg (110 lbs)
• women: body weight greater than or equal to 45kg (100 lbs)
• BMI between 18.5 - 35 kg/m2

Exclusion Criteria:

• Females who are nursing or pregnant.
• history of inflammatory bowel disease
• history of gastric ulcers within 12 months of signing the informed consent form
• tobacco users